Catalyst Wire Dossier Catalyst Wire Dossier

AAV2-hRPE65 gene therapy

AAV2-hRPE65
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AAV2-hRPE65 gene therapy, covering 2018-04-10 to 2018-04-10. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations [Phase 1]

See pricing